New framework aims to improve cancer care planning for seniors
NCT ID NCT05408507
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a new care planning method called ABC123 is practical and acceptable for people over 60 with advanced, incurable cancer. About 70 participants will try the framework during their first oncology visit, combining geriatric, cancer, and palliative care. Researchers will track how many people join, complete sessions, and follow up for 6 months to see if the approach works in real-world clinics.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2022
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Provision to sign and date the consent form 2. Age \>65 years old, or \>60 with at least one deficit on a geriatric screen. 3. Stated willingness to comply with all study procedures and be available for the duration of the study 4. Diagnosis of a solid-tumor cancer that is not curable with surgery or radiation within the 6 mos. prior to consenting. And that would potentially be treated with systemic cytotoxic chemotherapy. If molecular marker status is pending for a particular tumor, patients may still be approached for enrollment in the study. 5. New patient consultation within the UCHealth Denver Metro system or newly diagnosed with recurrent metastatic/incurable disease 6. English speaking only for the pilot portion Exclusion Criteria: 1. Have a diagnosis of a different advanced cancer that has required systemic therapy 2. Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a video game teach cancer patients to tame their pain?
- Real-World melanoma care under the microscope
- Can a single psychedelic dose ease despair in advanced cancer?
- Can tracking symptoms improve care for children with advanced cancer?
- Can a new pill boost Immunotherapy's power against advanced tumors?
- Can a DNA vaccine train the immune system to hunt down HER3-Positive cancers?